Cover Image
市場調查報告書

PharmaPoint:重度憂鬱症 - 現在/未來的主要企業

Major Depressive Disorder - Current and Future Players

出版商 GlobalData 商品編碼 305491
出版日期 內容資訊 英文 136 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:重度憂鬱症 - 現在/未來的主要企業 Major Depressive Disorder - Current and Future Players
出版日期: 2016年10月05日 內容資訊: 英文 136 Pages
簡介

本報告提供急速成長中的全球重度憂鬱症治療藥市場相關資料,以包含新加入之競爭情勢為焦點,彙整競爭評估,企業簡介,營業內容,財務狀況,策略評估與未來方案等詳細分析。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場

第4章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Lundbeck
    • Forest Laboratories (Actavis)
    • Eli Lilly
    • Pfizer
    • 大塚製藥
    • AstraZeneca
    • 武田醫藥品
    • Alkermes
    • Euthymics Bioscience
    • Naurex
    • e-Therapeutics

第5章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC1069FPR

GlobalData has released its pharma report, "Major Depressive Disorder - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MDD Market. The report identifies and analyses the key companies shaping and driving the global MDD market. The report provides insight into the competitive MDD landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for MDD
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of MDD sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving MDD market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global MDD market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Related Reports 7
  • 2.2 Upcoming Related Reports 8

3 Market Outlook 9

  • 3.1 Global Markets 9
    • 3.1.1 Forecast 9
    • 3.1.2 Drivers and Barriers - Global Issues 16

4 Current and Future Players 17

  • 4.1 Overview 17
  • 4.2 Trends in Corporate Strategy 19
  • 4.3 Company Profiles 20
    • 4.3.1 Allergan 20
    • 4.3.2 e-Therapeutics 23
    • 4.3.3 Alkermes 25
    • 4.3.4 Pfizer 27
    • 4.3.5 Otsuka 29
    • 4.3.6 Janssen 32
    • 4.3.7 Eli Lilly 35
    • 4.3.8 Lundbeck 37
    • 4.3.9 Takeda 40
    • 4.3.10 Axsome Therapeutics 42

5 Appendix 44

  • 5.1 Bibliography 44
  • 5.2 Abbreviations 90
  • 5.3 Methodology 101
  • 5.4 Forecasting Methodology 101
    • 5.4.1 Diagnosed NSCLC Patients 101
    • 5.4.2 Percent Drug-Treated Patients 102
    • 5.4.3 Drugs Included in Each Therapeutic Class 102
    • 5.4.4 Launch and Patent Expiry Dates 105
    • 5.4.5 General Pricing Assumptions 107
    • 5.4.6 Individual Drug Assumptions 109
    • 5.4.7 Generic Erosion 123
    • 5.4.8 Pricing of Pipeline Agents 123
  • 5.5 Primary Research - KOLs 128
    • 5.5.1 KOLs 128
  • 5.6 About the Authors 132
    • 5.6.1 Analyst 132
    • 5.6.2 Therapy Area Director 132
    • 5.6.3 Epidemiologist 133
    • 5.6.4 Global Head of Healthcare 133
  • 5.7 About GlobalData 135
  • 5.8 Disclaimer 135

List of Tables

  • Table 1: MDD Market - Drivers and Barriers, 2015-2025 16
  • Table 2: Key Companies in the MDD Market in the 7MM 18
  • Table 3: Allergan's MDD Portfolio Assessment, 2016 22
  • Table 4: Allergan SWOT Analysis in MDD, 2015-2025 23
  • Table 5: e-Therapeutics' MDD Portfolio Assessment, 2016 24
  • Table 6: e-Therapeutics SWOT Analysis in MDD, 2015-2025 25
  • Table 7: Alkermes' MDD Portfolio Assessment, 2016 27
  • Table 8: Alkermes SWOT Analysis in MDD, 2015-2025 27
  • Table 9: Pfizer's MDD Portfolio Assessment, 2016 28
  • Table 10: Pfizer SWOT Analysis in MDD, 2015-2025 29
  • Table 11: Otsuka's MDD Portfolio Assessment, 2016 31
  • Table 12: Otsuka SWOT Analysis in MDD, 2015-2025 32
  • Table 13: Janssen's MDD Portfolio Assessment, 2016 34
  • Table 14: Janssen SWOT Analysis in MDD, 2015-2025 35
  • Table 15: Eli Lilly's MDD Portfolio Assessment, 2016 36
  • Table 16: Eli Lilly SWOT Analysis in MDD, 2015-2025 37
  • Table 17: Lundbeck's MDD Portfolio Assessment, 2016 39
  • Table 18: Lundbeck SWOT Analysis in MDD, 2015-2025 40
  • Table 19: Takeda's MDD Portfolio Assessment, 2016 41
  • Table 20: Takeda SWOT Analysis in MDD, 2015-2025 41
  • Table 21: Axsome Therapeutics' MDD Portfolio Assessment, 2016 43
  • Table 22: Axsome Therapeutics SWOT Analysis in MDD, 2015-2025 43
  • Table 23: Key Launch Dates - Part I 105
  • Table 24: Key Launch Dates - Part II 106
  • Table 25: Key Patent Expiries 107

Table 26 Average Body Weight and Surface Area Across the 8MM 108

  • Table 27: Average Cost of Therapy of Alimta in the 8MM 110
  • Table 28: Average Cost of Therapy of Alecensa in the 8MM 111
  • Table 29: Average Cost of Therapy of Avastin 112
  • Table 30: Average Cost of Therapy of Cyramza 112
  • Table 31: Average Cost of Therapy of Gilotrif 113
  • Table 32: Average Cost of Therapy of Iressa 114
  • Table 33: Average Cost of Therapy of Portrazza 115
  • Table 34: Average Cost of Therapy of Tagrisso 116
  • Table 35: Average Cost of Therapy of Tarceva 117
  • Table 36: Average Cost of Therapy of Vargatef 117
  • Table 37: Average Cost of Therapy of Xalkori 118
  • Table 38: Average Cost of Therapy of Zykadia 119
  • Table 39: Average Cost of Therapy of Keytruda 120
  • Table 40: Average Cost of Therapy of Opdivo 121
  • Table 41: Average Cost of Therapy of Tecentriq 122
  • Table 42: Average Cost of Therapy of Conmana 123
  • Table 43: High-Prescribing Physicians Surveyed by Country 131

List of Figures

  • Figure 1: Global Sales by Region for MDD Therapies, 2015 and 2025 12
  • Figure 2: Global Sales by Region for MDD Therapies, 2015-2025 13
  • Figure 3: Global Sales by Drug Class for MDD Therapies, 2015 and 2025 14
  • Figure 4: Global Sales by Drug Class for MDD Therapies, 2015-2025 15
  • Figure 5: Company Portfolio Gap Analysis in MDD, 2015-2025 19
Back to Top